Custom Antibody Industry Segmentation, Parameters and Prospects by 2030

 

The global custom antibody market was valued at USD 147.6 million in 2022 and is projected to reach USD 301.7 million by 2030, expanding at a CAGR of 9.7% from 2023 to 2030. This growth is largely driven by the rising demand for personalized diagnostic and therapeutic treatments, which has encouraged key market players to invest in new product development, advanced service offerings, and expansion strategies.

For example, in January 2023, Creative Biolabs launched a series of services, including therapeutic antibodies, aimed at expanding its therapeutic segment. This move is part of the company’s broader effort to provide comprehensive therapeutic antibody development solutions, enabling it to serve both diagnostic and drug discovery needs more effectively. Similarly, Bio-Rad Laboratories, Inc., in November 2022, introduced the Pioneer Antibody Discovery Platform, a next-generation service designed to accelerate biologic candidate discovery. This platform leverages a phage display library containing over 200 billion exclusive sequences and incorporates the advanced SpyDisplay technology, making it possible to identify therapeutic antibody candidates tailored to specific client requirements. Importantly, antibodies developed through this platform are provided with complete sequence data, detailed characterization, and data packages, supporting end-users in both research and clinical applications.

Such technological advancements are reshaping the custom antibody development workflow, making it more efficient and precise, while simultaneously supporting the growing demand for tailored solutions in areas like therapeutics, diagnostics, and biomedical research.

Key Market Trends & Insights:

  • Regional Outlook: North America dominated the market in 2022, accounting for 44.9% of the total share, due to its advanced healthcare infrastructure, strong research ecosystem, and presence of leading biotech firms. The Asia Pacific region is projected to grow at the fastest pace during the forecast period, fueled by increasing investments in biotechnology, rising prevalence of infectious and chronic diseases, and expanding research activities in countries like China and India.
  • By Type: The monoclonal antibodies segment represented the largest share of the custom antibody market in 2022, contributing 50.6%. Meanwhile, the recombinant antibodies segment is expected to grow rapidly, registering a CAGR of 11.9% between 2023 and 2030, driven by their high specificity, reproducibility, and expanding role in drug development.
  • By Service: The antibody development segment accounted for the largest share at 54.2% in 2022, reflecting the strong demand for tailored antibody creation to support both academic research and therapeutic innovations.
  • By Application: The infectious disease segment held the highest share at 27.3% in 2022 and is projected to maintain dominance, supported by the rising global burden of infectious diseases and the need for effective diagnostic and therapeutic antibodies.
  • By End Use: The academic and research institutes segment captured the largest market share in 2022 and is expected to remain dominant, with the fastest CAGR of 10.8% during the forecast period. Increasing research funding, collaborations, and demand for customized solutions are driving this trend.

Order a free sample PDF of the Custom Antibody Market Intelligence Study, published by Grand View Research.

Market Size & Forecast:

  • 2022 Market Size: USD 147.6 Million
  • 2030 Projected Market Size: USD 301.7 Million
  • CAGR (2023-2030): 9.7%
  • North America: Largest market in 2022
  • Asia Pacific: Fastest growing market

Key Companies & Market Share Insights:

The steady demand for custom antibodies across pharma, biotech, diagnostics, and research institutions has created significant opportunities for both established players and emerging companies. Industry participants are actively engaging in collaborations, partnerships, and acquisitions to strengthen their portfolios and expand their global reach.

For example, in January 2023, Adimab announced that it had entered into partnerships with 11 companies in 2022 alone, further expanding its footprint in therapeutic antibody discovery and optimization. By early 2023, the company had collaborated with more than 105 organizations, underlining its position as a major contributor to antibody innovation and therapeutic development.

Such strategic initiatives, combined with technological advancements, are expected to accelerate the adoption of custom antibodies and support the market’s robust growth trajectory.

Key Players

  • Thermo Fisher Scientific Inc.
  • Creative Diagnostics
  • Abcam plc
  • Bio-Rad Laboratories, Inc
  • Kaneka Eurogentec S.A.
  • YenZym Antibodies, LLC.
  • Abmart
  • Labcorp Drug Development
  • LifeSpan BioSciences, Inc
  • GenScript

Explore Horizon Databook – The world's most expansive market intelligence platform developed by Grand View Research.

Conclusion:

The global custom antibody market is set for strong growth, driven by rising demand for personalized diagnostics and therapeutics, along with rapid technological advancements in antibody development platforms. North America currently leads the market, while Asia Pacific is poised for the fastest expansion. Monoclonal antibodies dominate the market, but recombinant antibodies are expected to grow rapidly. With academic and research institutes playing a key role and companies like Bio-Rad, Creative Biolabs, and Adimab advancing innovative solutions through partnerships and new platforms, the market is well-positioned for significant expansion through 2030.

Comments

Popular posts from this blog

Fuel Cell Industry Size & Share Analysis by Type and Region, Forecast Report, 2030

Squalene Industry In-depth Analysis and Forecast Report, 2030

Gardening Equipment Market Scope, Demands, Technological Development and Competitive Insights to 2025